ASH®-SAP American Society of Hematology Self-Assessment Program

SIXTH EDITION

BK-ASH-SAP_6E-150511-FM.indd 1 4/29/2016 3:59:06 PM Disclosures

As a provider accredited by the Accreditation Council for Research Society of North America (HTRS); Continuing Medical Education (ACCME), the American member of an advisory board for GlaxoSmithKline. Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational ac- Chapter 4, Hematopoietic growth factors tivities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing Aaron T. Gerds declares no competing financial interest. health care goods or services that have occurred within 24 Alan E. Lichtin declares no competing financial interest. months from the start of or during the production of the work and that are relevant to the author’s content. If an au- Chapter 5, Iron metabolism, iron overload, thor has such a financial interest, then she or he must dis- and the porphyrias close the name of the commercial interest and nature of the relationship (eg, consultant, grantee, etc.). An author who Heather A. Leitch has received honoraria, research funding, has no such financial relationship must declare that she or and/or served on advisory boards for Alexion, Apo-Pharma, he has nothing to disclose. The intent of this disclosure is Celgene, and Novartis. She is a member of the Exjade speak- not to prevent an author with a significant financial or other ers’ bureau. Jecko Thachil declares no competing financial relationship from making a presentation, but rather to pro- interest. vide readers with information that they can use to make their own judgments. It remains for the audience to determine Chapter 6, Acquired underproduction anemias whether the author’s interests or relationships may influence the work with regard to exposition or conclusion. Siobán B. Keel declares no competing financial interest. Narla Mohandas declares no competing financial interest.

Disclosures of financial relationships Chapter 7, Hemolytic anemias Chapter 1, Molecular basis of hematology Farzana A. Sayani declares no competing financial interest. Laura Schuettpelz declares no competing financial interest. Sophie Lanzkron: research funding: Novartis, Glycomimet- Omar Abdel-Wahab declares no competing financial interest. ics, Emmaus.

Chapter 2, Consultative hematology I: Chapter 8, and thrombophilia hospital-based and selected outpatient topics David Garcia: consultancy: Bristol-Myers Squibb, Portola, Cindy Neunert: safety advisory board: Genzyme. Anita Ra- Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. Saskia jasekhar: consultancy: Alexion, Octapharma, Bayer, Baxter; Middeldorp: consulting fees from Bayer, Boehringer Ingel- funding: American Society of Hematology. heim, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo and research support from GlaxoSmithKline, Aspen, the alliance of Bristol-Myers Squibb and Pfizer, and Sanquin Blood Sup- Chapter 3, Consultative hematology II: ply. Anjali Alatkar Sharathkumar: consulting fees from Bax- women’s health issues ter, CSL Behring, and Biogen Idec. Margaret V. Ragni: research support from Alnylam, ATHN, Baxalta, Biogen, CSL Behring, Dimension, Genentech Chapter 9, Bleeding disorders Roche, Novo Nordisk, Novartis, Opko, Pfizer, Shire, SPARK, and Vascular Medicine Institute; consultant for Baxter, Christine L. Kempton: consultancy: Baxter Healthcare, Biogen Bio-Marin, Biogen, Medscape, Opko, Tacere Therapeutics; Idec, Kedrion Biopharma; research support: Novo Nordisk. member of the National Hemophilia Foundation Medical & Jorge A. Di Paola: Consultancy: CSL Behring; DSMB Pfizer. Scientific Advisory Committee and a member of the Foun- dation for Women and Girls with Blood Disorders Advisory Chapter 10, Disorders of platelet number and Board. ­Peter A. Kouides: consultant for Baxter, CSL Behring, function Grifols; member of the National Blood Clot Alliance Medi- cal & Scientific Advisory Board. Sarah H. O’Brien: research Adam Cuker: consultancy: Amgen, Bracco, Genzyme; rese­ support from Bayer and the Hemophilia Thrombosis and arch support: Diagnostica Stago, T2 Biosystems. Andreas

xvi |

BK-ASH-SAP_6E-150511-FM.indd 16 4/29/2016 3:59:08 PM Disclosures | xvii

Greinacher: consultancy: Bayer Healthcare, Boehringer board: Incyte, Novartis, Celgene, MEI Pharma, Takeda, and Ingelheim, ASPEN, Instrumentation Laboratory; honoraria: Genoptix. Bristol Myers Squibb. Chapter 18, Acute myeloid leukemia Chapter 11, Laboratory hematology B. Douglas Smith declares no competing financial interest. John L. Frater declares no competing financial interest. Anne Eytan M. Stein declares no competing financial interest. M. Winkler declares no competing financial interest. Chapter 19, Acute lymphoblastic leukemia and lymphoblastic lymphoma Chapter 12, Transfusion medicine Mark R. Litzow: research funding from Amgen. Mats Hey- William Savage received research funding from Fresenius- man: no competing financial interest. Kabi. Suzanne Bakdash declares no competing financial interest. Chapter 20, Hodgkin lymphoma

Chapter 13, Cellular basis of hematopoiesis Ann S. LaCasce: research funding: Seattle Genetics. Andreas and stem cell transplantation Engert: consultancy, presentation, and research funding: Takeda and Millennium. Paresh Vyas declares no competing financial interest.Aly Karsan declares no competing financial interest. Chapter 21, Non-Hodgkin lymphoma Brad Kahl: research support: Genentech and AbbVie; consul- Chapter 14, Clinical hematopoietic cell tancy: Celgene, Roche, Seattle Genetics, Millennium, Infinity, transplantation and Cell Therapeutics. Greg Nowakowski: research support: Matthew Wieduwilt: research funding: Sigma Tau. Sergio Celgene and Bayer; consultancy: Celgene, Bayer, and Seattle A. Giralt: consultancy: Celgene; research funding: Celgene; Genetics. David Yang: no competing financial interest. Sanofi-Aventis; Honoraria: Celgene, Millennium, Sanofi- Aventis; speakers’ bureau: Sanofi-Aventis. Chapter 22, Chronic lymphocytic leukemia/ small lymphocytic lymphoma Chapter 15, Myeloid disorders and inherited Clive S. Zent: research funding from Novartis, Biothera, marrow failure syndromes GlaxoSmithKline, Genzyme, and Genentech. Timothy G. Alison A. Bertuch: research funding: Cancer Prevention Call: no conflicts of interest to declare. Research Institute of Texas, National Institutes of Health, American Society of Hematology. Inderjeet Dokal: research Chapter 23, Plasma cell disorders funding: MRC, Children with Cancer, Leukaemia & Lym- Shaji K. Kumar: consultancy: Celgene, Millennium, Onyx, phoma Research. Janssen, Bristol-Myers Squibb, Sanofi, and Skyline Diagnos- tics; research funding: Celgene, Millennium, Onyx, Janssen, Chapter 16, Chronic myeloid leukemia and Bristol-Myers Squibb, Sanofi, and Novartis. Jesús San Miguel: myeloproliferative neoplasms consultancy: Janssen, Novartis, Celgene, Millennium, Onyx, Bristol-Myers Squibb, and Sanofi. Ruben A. Mesa: consulting: Novartis; research support: ­Incyte, Gilead, Genentech, CTI, Promedior, and NS Pharma. Brady L. Stein: advisory board/consulting for Incyte ­Corporation. Discussion of off-label drug use

Chapter 17, Acquired marrow failure In compliance with ACCME policy, the American Society of syndromes: aplastic anemia, paroxysmal Hematology requires all authors to disclose any discussion of nocturnal hemoglobinuria, and off-label drug use in their chapters. myelodysplastic syndromes Chapter 1, Molecular basis of hematology Phillip Scheinberg: speaker: Novartis. Amy E. DeZern: no competing financial interest. David P. Steensma: advisory No discussion of off-label drug use.

BK-ASH-SAP_6E-150511-FM.indd 17 4/29/2016 3:59:08 PM xviii | Disclosures

Chapter 2, Consultative hematology I: Chapter 8, Thrombosis and thrombophilia hospital-based and selected outpatient topics No discussion of off-label drug use. Cindy Neunert: corticosteroids and rituximab for use in thrombotic thrombocytopenic purpura; antithrombin III Chapter 9, Bleeding disorders and activated protein C for disseminated intravascular coag- ulation; cyclophosphamide, corticosteroids, intravenous Recombinant factor VIIa for management of bleeding in immunoglobulin, and rituximab for catastrophic antiphos- hemophilia at doses and regimens that are not approved pholipid antibody syndrome; corticosteroids, intravenous and for other off-label indications, as well as prothrombin immunoglobulin, rituximab, and thrombopoietin receptor complex concentrates for treatment of factor II and X defi- agonists for pediatric immune thrombocytopenia (ITP); ciency. rituximab for adult ITP; and granulocyte-stimulating factor outside of severe congenital neutropenia. Anita Rajasekhar: Chapter 10, Disorders of platelet number desmopressin for use in platelet function disorders; desmo- and function pressin, recombinant factor VIIa, prothrombin complex concentrate, activated prothrombin complex concentrate, Desmopressin for inherited platelet function defects and glue, and,ε -, and uremic platelets, recombinant factor VIIa for inherited for use in surgical bleeding; conjugated estrogens for use in platelet function defects, rituximab for immune thrombo- uremic bleeding; intravenous immunoglobulin and erythro- cytopenia and thrombotic thrombocytopenic purpura, and poietin for use in parvovirus-associated pure red cell aplasia; fondaparinux and bivalirudin for heparin-induced throm- angiotensin-converting inhibitors and angiotensin bocytopenia. receptor blockers for use in post–renal transplant erythro- + cytosis; and rituximab for use in CD20 posttransplant lym- Chapter 11, Laboratory hematology phoproliferative disorder. No discussion of off-label drug use.

Chapter 3, Consultative hematology II: women’s health issues Chapter 12, Transfusion medicine Margaret V. Ragni: not applicable. Peter A. Kouides: low- No discussion of off-label drug use. molecular-weight heparin, fondaparinux, aspirin, and war- farin in pregnancy. Sarah H. O’Brien: not applicable. Chapter 13, Cellular basis of hematopoiesis and stem cell transplantation Chapter 4, Hematopoietic growth factors No discussion of off-label drug use. Aaron T. Gerds: filgrastim in HIV. Alan E. Lichtin: epoetin alfa and darbepoetin alfa in myelodysplastic syndromes. Chapter 14, Clinical hematopoietic cell transplantation Chapter 5, Iron metabolism, iron overload, Matthew Wieduwilt and Sergio A. Giralt: drug therapy for and the porphyrias hematologic malignancies and hematopoietic cell transplan- Off-label use of iron chelation therapy. tation.

Chapter 6, Acquired underproduction anemias Chapter 15, Myeloid disorders and inherited marrow failure syndromes No discussion of off-label drug use. No discussion of off-label drug use. Chapter 7, Hemolytic anemias Chapter 16, Chronic myeloid leukemia and Rituximab, cyclophosphamide, azathioprine, mycopheno- myeloproliferative neoplasms late mofetil, cyclosporine, and danazol in the treatment of autoimmune hemolytic anemia. No discussion of off-label drug use.

BK-ASH-SAP_6E-150511-FM.indd 18 4/29/2016 3:59:08 PM Disclosures | xix

Chapter 17, Acquired marrow failure Chapter 20, Hodgkin lymphoma syndromes: aplastic anemia, paroxysmal Ann S. LaCasce: rituximab for the treatment of lymphocyte- nocturnal hemoglobinuria, and predominant Hodgkin lymphoma. Andreas Engert: not myelodysplastic syndromes applicable. Phillip Scheinberg: cyclosporine, rabbit antithymocyte globu- lin, alemtuzumab, and cyclophosphamide. Amy E. DeZern: Chapter 21, Non-Hodgkin lymphoma not applicable. David P. Steensma: , , lenalidomide for non-del5q, darbepoetin, and epoetin. No discussion of off-label drug use.

Chapter 18, Acute myeloid leukemia Chapter 22, Chronic lymphocytic leukemia/ small lymphocytic lymphoma No discussion of off-label drug use. Idelalisib, ibrutinib, ofatumumab, pentostatin, and ­cladribine. Chapter 19, Acute lymphoblastic leukemia and lymphoblastic lymphoma Chapter 23, Plasma cell disorders Mark R. Litzow and Mats Heyman: blinatumomab, dasat- inib, and ponatinib. No discussion of off-label drug use.

BK-ASH-SAP_6E-150511-FM.indd 19 4/29/2016 3:59:08 PM